WAM
EIGR

Wealthspire Advisors (Maryland)’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Wealthspire Advisors (Maryland)’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-2
Closed -$1K – 2186
2019
Q1 		$1K Buy
2
+1
+100% +$401 ﹤0.01% 2421
2018
Q4 		$0 Hold
1
– – ﹤0.01% 2598
2018
Q3 		$0 Hold
1
– – ﹤0.01% 2546
2018
Q2 		$0 Hold
1
– – ﹤0.01% 2615
2018
Q1 		$0 Hold
1
– – ﹤0.01% 2674
2017
Q4 		$0 Hold
1
– – ﹤0.01% 2585
2017
Q3 		$0 Buy
+1
New +$272 ﹤0.01% 2508

Other funds holding EIGR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Wealthspire Advisors (Maryland)'s EIGR Position: Q2 2019 in Review

Wealthspire Advisors (Maryland) sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2019, closing a stake of 2 shares — an estimated $1K sold.

Wealthspire Advisors (Maryland) first reported a position in EIGR in Q3 2017 and held it in 7 quarters. The position peaked at $1K in Q1 2019. 78 funds tracked by Wall St. Rank hold EIGR as of Q2 2019.

  • Wealthspire Advisors (Maryland) reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
  • Wealthspire Advisors (Maryland) sold 2 Eiger BioPharmaceuticals, Inc. shares in Q2 2019, an estimated $1K.
  • Wealthspire Advisors (Maryland) first reported a position in Eiger BioPharmaceuticals, Inc. in Q3 2017 and held it in 7 quarters.
  • Wealthspire Advisors (Maryland)'s Eiger BioPharmaceuticals, Inc. position peaked at $1K in Q1 2019.
  • 78 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2019.

Based on Wealthspire Advisors (Maryland)'s 13F filing for Q2 2019, filed 12 Aug 2019.